Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › brentuximab vedotin

brentuximab vedotin

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of brentuximab vedotin

38 trials tracked of brentuximab vedotin: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 721 citations.

38Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 4 Phase 2 29 Phase 1 1 Other / NA 1
  1. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 721 cited
  2. Phase 3 A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) Completed · 579 cited
  3. Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 322 cited
  4. Phase 4 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Completed
  5. Phase 4 Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Completed
  6. Phase 4 A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma Completed
Show 32 more trials
  1. Phase 3 A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) Completed
  2. Phase 2 A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Completed
  3. Phase 2 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Completed
  4. Phase 2 Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Completed
  5. Phase 2 A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma Completed
  6. Phase 2 An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas Completed
  7. Phase 2 Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas Completed
  8. Phase 2 Brentuximab Vedotin for Systemic Sclerosis Completed
  9. Phase 2 Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma Completed
  10. Phase 2 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma Completed
  11. Phase 2 A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Completed
  12. Phase 2 Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level Completed
  13. Phase 2 A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Completed
  14. Phase 2 Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Completed
  15. Phase 2 Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Completed
  16. Phase 2 Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
  17. Phase 2 Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma Completed
  18. Phase 2 A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment Completed
  19. Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma Completed
  20. Phase 2 A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma Completed
  21. Phase 2 Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients Completed
  22. Phase 2 Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
  23. Phase 2 A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) Completed
  24. Phase 2 A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression Completed
  25. Phase 2 A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL Completed
  26. Phase 2 A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma Completed
  27. Phase 2 Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Completed
  28. Phase 2 Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Completed
  29. Phase 2 Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Completed
  30. Phase 2 Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma Completed
  31. Phase 1 A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Completed
  32. N/A Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
Oncology Sys. Review
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Frontiers Jun 4, 2026
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma
Allergy & Immunology Sys. Review
Ven-Chi-Dec Regimen Induces Remission in Refractory Hodgkin Lymphoma Venetoclax combo shows promise for relapsed Hodgkin lymphoma
A 26-year-old with relapsed/refractory classical Hodgkin lymphoma achieved complete metabolic remission after 6 cycles of venetoclax, chidam…
A 26-year-old man with relapsed Hodgkin lymphoma achieved complete remission after a novel three-drug regimen, with no significant side effe…
Frontiers May 15, 2026
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients
Oncology Phase II
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Blood Apr 12, 2026